Halak Brian K 4
4 · Dicerna Pharmaceuticals Inc · Filed Nov 6, 2018
Insider Transaction Report
Form 4
Halak Brian K
Director10% Owner
Transactions
- Sale
Common Stock
2018-11-02$13.47/sh−189,359$2,550,666→ 2,729,697 total(indirect: By Domain Partners VIII, L.P.) - Sale
Common Stock
2018-11-05$12.98/sh−39,606$514,086→ 2,690,091 total(indirect: By Domain Partners VIII, L.P.) - Sale
Common Stock
2018-11-06$13.18/sh−102,067$1,345,243→ 2,588,024 total(indirect: By Domain Partners VIII, L.P.) - Sale
Common Stock
2018-11-06$13.18/sh−761$10,030→ 19,161 total(indirect: By DP VIII Associates, L.P.) - Sale
Common Stock
2018-11-06$14.16/sh−1,489$21,084→ 2,586,535 total(indirect: By Domain Partners VIII, L.P.) - Sale
Common Stock
2018-11-06$14.16/sh−11$156→ 19,150 total(indirect: By DP VIII Associates, L.P.) - Sale
Common Stock
2018-11-02$13.47/sh−1,412$19,020→ 20,217 total(indirect: By DP VIII Associates, L.P.) - Sale
Common Stock
2018-11-05$12.98/sh−295$3,829→ 19,922 total(indirect: By DP VIII Associates, L.P.)
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]The Reporting Person is a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction (4)(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his pecuniary interest therein and/or that are not actually distributed to him.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.899. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.